Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.10
−$0.17 · -5.20%
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Previous close
$3.10
−$0.17 · -5.20%
Regular session · ET · Market data may be delayed.
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Day range
Current $3.10
52-week range
Current $3.10
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
50
Mixed
Risk
41
Elevated Risk
Momentum
61
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Day range
Current $3.10
52-week range
Current $3.10
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 830K USD | — | — | — | 50K USD |
| Gross profit | −830K USD | — | — | — | −50K USD |
| Research and development | 48.26M USD | 43.8M USD | 32.12M USD | 25.86M USD | 28.12M USD |
| Selling, general, and administrative | 14.69M USD | 10.59M USD | 4.82M USD | 3.9M USD | 11.65M USD |
| Operating expenses | 62.12M USD | 54.39M USD | 36.93M USD | 29.77M USD | 39.77M USD |
| Interest income | 3.44M USD | 2.01M USD | 1.62M USD | 254K USD | — |
| Interest expense | — | 300K USD | — | — | — |
| Depreciation and amortization | 830K USD | 662K USD | 560K USD | 387K USD | 50K USD |
| Operating income | −62.95M USD | −54.39M USD | −36.93M USD | −29.77M USD | −39.82M USD |
| Net income | −59.52M USD | −52.67M USD | −35.31M USD | −29.51M USD | −39.77M USD |
Company facts updated Sep 14, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$14.00
351.61% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 7, 2024 | 1:10 | — | — |
Effective Oct 7, 2024
1:10
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
